(Q45046883)

8 December 2017

Characterization of a DNA vaccine expressing a human immunodeficiency virus-like particle (English)

1 reference

8 December 2017

Kelly R Young

1

1 reference

8 December 2017

James M Smith

series ordinal

2

1 reference

8 December 2017

Ted M Ross

series ordinal

3

1 reference

8 December 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

8 December 2017

1 reference

8 December 2017

327

1 reference

8 December 2017

2

1 reference

8 December 2017

262-272

1 reference

Human Immunodeficiency Virus Type 1 Env with an Intersubunit Disulfide Bond Engages Coreceptors but Requires Bond Reduction after Engagement To Induce Fusion

8 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Replication of lentiviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

DNA vaccination of macaques by a full-genome simian/human immunodeficiency virus type 1 plasmid chimera that produces non-infectious virus particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Mutational analysis of two zinc-finger motifs in the nucleocapsid protein of simian immunodeficiency virus mac239.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Recent Insights into HIV Accessory Proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Nuclear mRNA export: insights from virology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Vaccine technology: looking to the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Complementation of integrase function in HIV-1 virions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Protection from pathogenic SIV challenge using multigenic DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Development of a multicomponent candidate vaccine for HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Active human immunodeficiency virus protease is required for viral infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Long-term effects of therapeutic vaccination with rgp 120

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Mutational analysis of two conserved sequence motifs in HIV-1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Defining the Protective Antibody Response for HIV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Cytotoxic T-lymphocyte responses to HIV-1 reverse transcriptase (review).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Mutational analysis of two zinc finger motifs in HIV type 1 nucleocapsid proteins: effects on proteolytic processing of Gag precursors and particle formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Adaptation of two primary human immunodeficiency virus type 1 isolates to growth in transformed T cell lines correlates with alterations in the responses of their envelope glycoproteins to soluble CD4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

The double-stranded RNA-binding protein Staufen is incorporated in human immunodeficiency virus type 1: evidence for a role in genomic RNA encapsidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV(mac)251 challenge in rhesus Macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

DNA vaccines for viral infections: basic studies and applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

HIV vaccine development: lessons from the past and promise for the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Mucosal HIV vaccines: where are we now?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Human Immunodeficiency Virus Type 1 N-Terminal Capsid Mutants Containing Cores with Abnormally High Levels of Capsid Protein and Virtually No Reverse Transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Preclinical AIDS vaccine research: survey of SIV, SHIV, and HIV challenge studies in vaccinated nonhuman primates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Highly sensitive qualitative and quantitative detection of reverse transcriptase activity: optimization, validation, and comparative analysis with other detection systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Virus-like particle and DNA-based candidate AIDS vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Particle-based vaccines for HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Alteration of zinc-binding residues of simian immunodeficiency virus p8(NC) results in subtle differences in gag processing and virion maturation associated with degradative loss of mutant NC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

inferred from DOI database lookup

7 January 2021

based on heuristic

Requirements for incorporation of Pr160gag-pol from human immunodeficiency virus type 1 into virus-like particles.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

inferred from DOI database lookup

7 January 2021

based on heuristic

Analysis of minimal human immunodeficiency virus type 1 gag coding sequences capable of virus-like particle assembly and release

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.07.009

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2004.07.009

1 reference

8 December 2017

1 reference